Measurement of the fraction of exhaled breath temperature as a biomarker of asthma control in patients in northeastern Mexico
Sunday, March 4, 2018
South Hall A2 (Convention Center)
Cindy Elizabeth de Lira-Quezada, MD, Sandra Nora Gonzalez-Diaz, MD, PhD, Alfredo Arias Cruz, MD FAAAAI, Barbara Elizondo Villarreal, MD, Carlos Macouzet-Sanchez, MD, Gabriela Galindo-Rodriguez, MD, PhD, Rosalaura Virginia Villarreal-Gonzalez, MD, Rosa Ivett Guzman-Avilan, MD, Daniel Sanchez-Guerra, MD, Emilio G Soto-Zamora, MD
RATIONALE: The measurement of the fraction of exhaled breath temperature has been used as a noninvasive biomarker in the detection of airway diseases. The purpose of our study was to compare the fraction of exhaled breath temperature (EBT) in patients with controlled and uncontrolled asthma to establish its use as a biomarker. EBT reports peripheral airway temperature (T3max), central (T1max) and the relationship between both (Rel T1/T3).

METHODS: We reviewed a total of 40 records of adult asthmatic patients that were consulted at the Regional Center of Allergy and Clinical Immunology at the University Hospital in Monterrey, Mexico and to whom the EBT was measured. Patients were classified as uncontrolled or controlled asthma by the Asthma Control Test and doses of inhaled corticosteroid were documented. EBT was compared among both group of patients. Data was analyzed using SPSS 23.0.

RESULTS: Nineteen patients (47.5%) had controlled asthma while 21 (52.5%) were uncontrolled. The mean of T3 max temperature in controlled asthma using low doses of corticosteroids was 29.5; in patients with uncontrolled asthma and higher doses of inhaled corticosteroids, the mean was 28.1 with p= 0.032.

CONCLUSIONS: Patients with uncontrolled asthma and higher doses of inhaled corticosteroids showed significant difference in EBT measurements compared to controlled asthma, establishing the EBT as a useful biomarker.